Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

NCT06772623 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

252

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Carcinoma

Interventions

DRUG: Telisotuzumab Adizutecan
DRUG: Budigalimab
DRUG: Pembrolizumab
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Cisplatin

Sponsor

AbbVie